Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence
Alimentary Pharmacology & Therapeutics2017Vol. 46(3), pp. 282–291
Citations Over TimeTop 10% of 2017 papers
Wolfgang Kruis, Vassilios Kardalinos, Thomas Eisenbach, M. Lukas, Tomás Vich, Ivan Bunganič, Juris Pokrotnieks, Jeļena Derova, Jūratė Kondrackienė, Rifaat Safadi, Daniel Tuculanu, Zsolt Tulassay, J Banai, A. Curtin, A.E. Dorofeyev, Salam Zakko, Nicola Ferreira, S Björck, M. M. Diez Alonso, Jyrki Mäkelä, Nicholas J. Talley, K. Dilger, Roland Greinwald, Ralf Mohrbacher, Robert E. Spiller
Abstract
Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.
Related Papers
- → Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double‐blind, randomized, placebo‐controlled study(2000)60 cited
- [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].(1992)
- → Schizophrenia: Do we really need placebo-controlled studies?(1998)20 cited
- → Anti-inflammatory Agents(2022)1 cited